Medtabs Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
- Revenue Growth 103.84%
- Profit Growth 318.94%
- Ebitda -46.88%
- Net Worth 2.10%
- Total Assets -15.55%
About Medtabs Pharma
Medtabs Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 July 2014 and has a history of Ten years and seven months. Its registered office is in Satara, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.00 M.
Sagar Doshi, Prashant Wankar, and Angha Apte serve as directors at the Company.
Company Details
- Location
Satara, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85100PN2014PTC151685
- Company No.
151685
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jul 2014
- Date of AGM
14 Dec 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Medtabs Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sagar Doshi  | Director | 03-Jul-2014 | Current |
| Prashant Wankar | Director | 27-Sep-2014 | Current |
| Angha Apte | Director | 27-Sep-2014 | Current |
Financial Performance of Medtabs Pharma.
Medtabs Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 103.84% increase. The company also saw a substantial improvement in profitability, with a 318.94% increase in profit. The company's net worth moved up by a moderate rise of 2.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medtabs Pharma?
In 2022, Medtabs Pharma had a promoter holding of 20.00% and a public holding of 80.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Apr 2024 | Others | ₹5.00 M | Open |
How Many Employees Work at Medtabs Pharma?
Unlock and access historical data on people associated with Medtabs Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medtabs Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medtabs Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
